Evaluation of pre transplant T-cell activation status by soluble CD 30 determination.
OBJECTIVE
To evaluate the utility of serum CD30 (sCD30) levels as predictor of early acute graft rejection in live related renal transplant programme.


METHODS
This prospective study included 50 consecutive renal transplant recipients who received their first live related renal allograft at the Sindh Institute of Urology and Transplantation (SIUT) between October 2006 and March 2007. Blood samples were obtained one day before transplantation and on the third and fourteenth posttransplant days. Blood samples were also obtained from 50, age and sex matched healthy control individuals. Levels of serum sCD30 were measured by Enzyme Linked Immunosorbent Assay (ELISA).


RESULTS
Donor-recipient blood group matching was identical in all patients. Pre-transplant lymphocyte crossmatch for T and B cells was negative, and panel reactive antibodies (PRA) were 0% for all recipients. The mean age of recipients was 31.6 +/- 10.23 years (range 5 to 55 years), while mean donor age was 32.74 +/- 8.48 years (range 21-50 years). Eleven (22%) recipients and donors were HLA identical while remaining (78%) were one haplotype match. Average serum sCD30 pre-transplant levels (37.8 +/- 4.97U/ml) were significantly higher than those of healthy individual's mean value of 8.48 +/- 4.97 U/ml, (P = 0.001). Eight (16%) patients developed acute rejection episode during this follow up period. Rejections were described and classified according to BANFF 97 classification.


CONCLUSIONS
In this small single center study the serum levels of sCD30 did not show any significant difference between rejection and non rejection group in our transplant population.
Abbas
Khawar
K
Department of Molecular Biology and Immunology, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan.
Muzaffar
Rana
R
Zafar
Mirza Naqi
MN
Mubarak
Muhammad
M
Naqvi
Syed Ali Anwar
SA
Rizvi
Syed Adibul Hassan
SA
D000293:Adolescent; D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000175:diagnosis* / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013601:T-Lymphocytes / Q000276:immunology*; D014019:Tissue Donors; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D017730:Ki-1 Antigen